| [1] |
Frauscher B, Gschliesser V, Brandauer E, et al. Video analysis of motor events in REM sleep behavior disorder[J]. Mov Disord, 2007, 22(10):1464-7140.
|
| [2] |
Wing YK, Lam SP, Li SX, et al. REM sleep behaviour disorder in Hong Kong Chinese: clinical outcome and gender comparison[J]. J Neurol Neurosurg Psychiatry, 2008, 79(12):1415-1416.
|
| [3] |
Zhang J, Lam SP, Ho CK, et al. Diagnosis of REM sleep behavior disorder by video-polysomnographic study: is one night enough[J]? Sleep, 2008, 31(8):1179-1185.
|
| [4] |
Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions[J]. Lancet Neurology, 2016, 15(4):405-419.
|
| [5] |
Wichniak A, Wierzbicka A, Walecka M, et al. Effects of Antidepressants on Sleep[J]. Curr Psychiatry Rep, 2017, 19(9):63.
|
| [6] |
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications[J]. Chest, 2014, 146(5):1387-1394.
|
| [7] |
Pujol M, Pujol J, Alonso T, et al. Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography[J]. Sleep Med, 2017, 40:116-121.
|
| [8] |
Rodriguez CL, Jaimchariyatam N, Budur K. Rapid eye movement sleep behavior disorder: A review of the literature and update on current concepts[J]. Chest, 2017, 152(3):650-662.
|
| [9] |
Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP[J]. Sleep, 2002, 25(2):120-138.
|
| [10] |
Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of REM sleep behavior disorder in the general population[J].Sleep, 2018, 41(2). doi: 10.1093/sleep/zsx197. |
| [11] |
Galbiati A, Verga L, Giora E, et al. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies[J]. Sleep Med Rev, 2019, 43:37-46.
|
| [12] |
Iranzo A, Santamaria J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder[J]. Ann Neurol, 2017, 82(3):419-428.
|
| [13] |
Postuma RB, Gagnon JF, Vendette M, et al. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder[J]. Ann Neurol, 2011, 69(5):811-818.
|
| [14] |
Sasai T, Matsuura M, Inoue Y. Electroencephalographic findings related with mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder[J]. Sleep, 2013, 36(12):1893-1899.
|
| [15] |
Genier Marchand D, Montplaisir J, Postuma RB, et al. Detecting the cognitive prodrome of dementia with lewy bodies: A prospective study of rem sleep behavior disorder[J]. Sleep, 2017, 40(1). doi: 10.1093/sleep/zsw014. |
| [16] |
Youn S, Kim T, Yoon IY, et al. Progression of cognitive impairments in idiopathic REM sleep behaviour disorder[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8):890-896.
|
| [17] |
Ferini-Strambi L, Marelli S, Galbiati A, et al. REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders[J]. Arch Ital Biol, 2014, 152(2-3):129-146.
|
| [18] |
中华医学会神经病学分会睡眠障碍学组.中国快速眼球运动睡眠期行为障碍诊断与治疗专家共识[J].中华神经科杂志，2017，50(8):567-571.
|
| [19] |
Kunz D, Bes F. Twenty years after: another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging[J]. Neuropsychobiology, 2017, 76(2):100-104.
|
| [20] |
Schenck CH, Bundlie SR, Ettinger MG, et al. Chronic behavioral disorders of human REM sleep: A new category of parasomnia[J]. Sleep, 1986, 9(2):293-308.
|
| [21] |
Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method[J]. Neurology, 1992, 42(7):1371-1374.
|
| [22] |
Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases[J]. Brain, 2000, 123(Pt 2):331-339.
|
| [23] |
Hendricks JC, Lager A, O'Brien D, et al. Movement disorders during sleep in cats and dogs[J]. J Am Vet Med Assoc, 1989, 194(5):686-689.
|
| [24] |
Shin C, Park H, Lee WW, et al. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial[J]. J Neurol Sci, 2019, 401:81-86.
|
| [25] |
Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam[J]. J Clin Sleep Med, 2009, 5(3):235-239.
|
| [26] |
McCarter SJ, Boswell CL, St Louis EK, et al. Treatment outcomes in REM sleep behavior disorder[J]. Sleep Med, 2013, 14(3):237-242.
|
| [27] |
Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease[J]. Brain, 2007, 130(Pt 11):2770-2788.
|
| [28] |
Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD)[J]. J Clin Sleep Med, 2010, 6(1):85-95.
|
| [29] |
Griebling TL. Re: American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults[J]. J Urol, 2019, 202(3):438.
|
| [30] |
Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism[J]. Clin Pharmacokinet, 2002, 41(12):913-958.
|
| [31] |
St Louis EK. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects[J]. Curr Neuropharmacol, 2009, 7(2):96-105.
|
| [32] |
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition[J]. Clin Pharmacokinet, 2000, 38(1):41-57.
|
| [33] |
Brzezinski A. Melatonin in humans[J]. N Engl J Med, 1997, 336(3):186-195.
|
| [34] |
Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder[J]. J Sleep Res, 2010, 19(4):591-596.
|
| [35] |
Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation[J]. Mov Disord, 1999, 14(3):507-511.
|
| [36] |
Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder[J]. Psychiatry Clin Neurosci, 2001, 55(3):267-269.
|
| [37] |
Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients[J]. Sleep Med, 2003, 4(4):281-284.
|
| [38] |
Kunz D. Melatonin in rapid eye movement sleep behavior disorder: why does it work[J]? Sleep Med, 2013, 14(8):705-706.
|
| [39] |
Kunz D, Mahlberg R, Muller C, et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials[J]. J Clin Endocrinol Metab, 2004, 89(1):128-134.
|
| [40] |
Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects[J]. Psychopharmacology (Berl), 1996, 126(2):179-181.
|
| [41] |
McGrane IR, Leung JG, St Louis EK, et al. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence[J]. Sleep Med, 2015, 16(1):19-26.
|
| [42] |
Arnaldi D, Antelmi E, St Louis EK, et al. Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk[J]? Sleep Med Rev, 2017, 36:82-95.
|
| [43] |
Seabra ML, Bignotto M, Pinto LR, et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment[J]. J Pineal Res, 2000, 29(4):193-200.
|
| [44] |
San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system[J]. Eur Psychiatry, 2008, 23(6):396-402.
|
| [45] |
Bonakis A, Economou NT, Papageorgiou SG, et al. Agomelatine may improve REM sleep behavior disorder symptoms[J]. J Clin Psychopharmacol, 2012, 32(5):732-734.
|
| [46] |
Shiromani PJ, Gillin JC, Henriksen SJ. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy[J]. Annu Rev Pharmacol Toxicol, 1987, 27:137-156.
|
| [47] |
Esaki Y, Kitajima T, Koike S, et al. An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder[J]. J Clin Sleep Med, 2016, 12(5):689-693.
|
| [48] |
Di Giacopo R, Fasano A, Quaranta D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease[J]. Mov Disord, 2012, 27(4):559-561.
|
| [49] |
Wang Y, Yang Y, Wu H, et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease[J]. J Clin Sleep Med, 2016, 12(10):1403-1409.
|
| [50] |
Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases[J]. Neurology, 2000, 55(6):870-871.
|
| [51] |
Yeh SB, Yeh PY, Schenck CH. Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease[J]. J Clin Sleep Med, 2010, 6(2):192-195.
|
| [52] |
Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder[J]. Parkinsonism Relat Disord, 2013,19(2):153-157.
|
| [53] |
Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series[J]. Sleep Med, 2006, 7(5):418-423.
|
| [54] |
Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease[J]. Sleep, 2008, 31(10):1418-1421.
|
| [55] |
Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease[J]. CNS Drugs, 2010, 24(11):941-968.
|
| [56] |
Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis[J]. Drug Saf, 2003, 26(6):439-444.
|
| [57] |
Tan SM, Wan YM. Pramipexole in the treatment of REM sleep behaviour disorder: A critical review[J]. Psychiatry Res, 2016, 243:365-372.
|
| [58] |
Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series[J]. J Clin Pharm Ther, 2014, 39(5):564-566.
|
| [59] |
Kozela E, Juknat A, Vogel Z. Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid[J]. Int J Mol Sci, 2017, 18(8). doi: 10.3390/ijms18081669. |
| [60] |
Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort[J]. Sleep Med, 2011, 12(5):445-453.
|
| [61] |
Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK)[J]. Sleep Med, 2010, 11(1):43-48.
|
| [62] |
Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease[J]. JAMA Neurol, 2015, 72(6):707-712.
|